GB0302882D0 - Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss - Google Patents

Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss

Info

Publication number
GB0302882D0
GB0302882D0 GBGB0302882.6A GB0302882A GB0302882D0 GB 0302882 D0 GB0302882 D0 GB 0302882D0 GB 0302882 A GB0302882 A GB 0302882A GB 0302882 D0 GB0302882 D0 GB 0302882D0
Authority
GB
United Kingdom
Prior art keywords
relating
agents
treatment
weight loss
cardiovascular dysfunction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0302882.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College Cardiff Consultants Ltd
Cardiff University
Original Assignee
University College Cardiff Consultants Ltd
Cardiff University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College Cardiff Consultants Ltd, Cardiff University filed Critical University College Cardiff Consultants Ltd
Priority to GBGB0302882.6A priority Critical patent/GB0302882D0/en
Publication of GB0302882D0 publication Critical patent/GB0302882D0/en
Priority to PCT/GB2004/000469 priority patent/WO2004069232A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
GBGB0302882.6A 2003-02-07 2003-02-07 Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss Ceased GB0302882D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0302882.6A GB0302882D0 (en) 2003-02-07 2003-02-07 Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss
PCT/GB2004/000469 WO2004069232A2 (en) 2003-02-07 2004-02-06 Egfr tyrosine kinase inhibitor for treating cardiovascular dysfunction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0302882.6A GB0302882D0 (en) 2003-02-07 2003-02-07 Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss

Publications (1)

Publication Number Publication Date
GB0302882D0 true GB0302882D0 (en) 2003-03-12

Family

ID=9952655

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0302882.6A Ceased GB0302882D0 (en) 2003-02-07 2003-02-07 Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss

Country Status (2)

Country Link
GB (1) GB0302882D0 (en)
WO (1) WO2004069232A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090717A1 (en) 2007-05-18 2009-07-18 Smithkline Beecham Corp QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
KR101328137B1 (en) 2011-12-23 2013-11-11 건국대학교 산학협력단 Composition for preventing or treating hypertension comprising PLCgamma or EGFR inhibitor
WO2013158482A1 (en) * 2012-04-20 2013-10-24 Brooks Marvin B Small molecule compounds for targeting inflammatory conditions
US9623003B1 (en) 2013-04-04 2017-04-18 Humanetics Corporation Method of mitigating long and short term detrimental effects of exposure to medical imaging ionizing radiation by administration of genistein
US9623004B2 (en) 2013-08-02 2017-04-18 Humanetics Corporation Administration of a therapeutic amount of genistein to mitigate erectile dysfunction resulting from radiation therapy for prostate cancer only throughout a defined administration period commencing shortly before and concluding after radiation therapy
KR101402254B1 (en) * 2013-09-16 2014-06-19 건국대학교 산학협력단 Composition for preventing or treating hypertension comprising PLCgamma or EGFR inhibitor
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
WO2018160178A1 (en) * 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1199768A (en) * 1966-10-31 1970-07-22 Pfizer & Co C Nitrogen Heterocycles and process for their preparation
SK283413B6 (en) * 1992-08-06 2003-07-01 Warner-Lambert Company 2-Thioindoles, 2-indolinethiones and polysulfides, their analogues (2-indolineselenone) (selenide), and pharmaceutical compositions based on them
EP2163546B1 (en) * 1995-03-30 2016-06-01 Pfizer Products Inc. Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
AU756515B2 (en) * 1998-03-13 2003-01-16 Johns Hopkins University School Of Medicine, The The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation

Also Published As

Publication number Publication date
WO2004069232A3 (en) 2004-11-04
WO2004069232A2 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
HK1110508A1 (en) Compositions and methods of their use for improving the condition and appearance of skin
GB2406523B (en) Improvements in and relating to the formation of knots
EP1758450A4 (en) Improvements in or relating to plant treatment agents
HK1097256A1 (en) Pyrizdazine derivatives and their use as therapeutic agents
GB2410919B (en) Improvements in or relating to the treatment of waste
EP1766092A4 (en) Target-specific compomers and methods of use
IL179560A0 (en) Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias
GB0302882D0 (en) Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss
GB0307352D0 (en) Improvements in and relating to the analysis of compounds
GB2389645B (en) Improvements in or relating to the treatment of molten materials
EP1755581A4 (en) Methods and compositions for the treatment of myocardial conditions
TWI365187B (en) 7-azaindoles and the use thereof as therapeutic agents
GB0310403D0 (en) Improvements in and relating to the control of centrifuges
GB2405192B (en) Improvements in and relating to the kilning of barley
GB0325195D0 (en) Improvements relating to the use of flasks in centrifugal evaporators
GB0405482D0 (en) Materials and methods relating to the treatment of glioblastomas
AU2003263988A8 (en) Methods and compositions to treat conditions associated with neovascularization
GB2378394B (en) Improvements in or relating to the game of golf
GB2405075B (en) Improvements in and relating to the steeping of barley
GB0300364D0 (en) Improvements in and relating to biocides
GB0308399D0 (en) Improvements in and relating to kettles
GB0309511D0 (en) Improvements relating to the use of flasks in centrifugal evaporators
GB0007217D0 (en) Materials and methods relating to the treatment of leukaemias
AU2003901028A0 (en) Improvements in and relating to the casting of metals
GB2404876B (en) Improvements in or relating to platform structures

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)